BenzingaMay 26, 7:30 AM ET▲ Positive
The company reported encouraging early clinical data showing strong specificity (88%) and positive predictive value (92%) for its diagnostic test. The advancement toward larger clinical validation studies and planned U.S. market entry represent significant progress. The test addresses a large unmet medical need with an estimated 21 million Long COVID patients in the U.S., representing substantial commercial opportunity.